JFJoshua R. Freeman

Joshua R. Freeman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua R. Freeman has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preconception sleep, pregnancy loss, and adverse pregnancy outcomes among women with a history of pregnancy loss

    by Joshua R Freeman, Brian W Whitcomb, Elizabeth R Bertone-Johnson, Louise M O’bRien, Galit L Dunietz, Alexandra C Purdue-Smithe, Keewan Kim, Robert M Silver, Enrique F Schisterman, Sunni L Mumford

    STUDY QUESTION: Are preconception sleep characteristics associated with pregnancy loss and adverse pregnancy outcomes? SUMMARY ANSWER: Preconception sleep characteristics were not associated with pregnancy loss, but earlier sleep midpoints were associated with lower risk of adverse pregnancy outcomes, while social jetlag >1 h was associated with greater risk of a composite of adverse pregnancy outcomes. WHAT IS KNOWN ALREADY: Short sleep duration in mid-pregnancy has been associated with risk of second-trimester pregnancy loss, preterm birth (PTB), and hypertensive disorders of pregnancy (HDP). The relationships between preconception sleep and pregnancy loss, and adverse pregnancy outcomes have not been well characterized, despite plausible links. STUDY DESIGN, SIZE, DURATION: This was a secondary analysis of a randomized controlled trial conducted between 2006 and 2012 that prospectively followed 1228 women who were attempting to become pregnant after a history of pregnancy loss. Women were followed for ≤6 cycles while attempting pregnancy, and throughout pregnancy if they conceived. Over the follow-up, 140 women withdrew from the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study evaluated baseline, self-reported preconception sleep duration, sleep latency, sleep midpoint, and social jetlag with risk of pregnancy loss and adverse pregnancy outcomes (e.g. PTB, HDP, and gestational diabetes (GDM)) among 1228 women with a history of pregnancy loss in the EAGeR trial. Pregnancy was documented by hCG tests; 797 women became pregnant over the follow-up. Pregnancy losses were defined as any loss after a positive hCG test; there were 188 pregnancy losses. PTB, HDP, and GDM cases were ascertained via medical record abstraction. PTB (n = 53), HDP (n = 62), and GDM (n = 22) were examined as a composite outcome (n = 118) and PTB and HDP were examined individually in exploratory analyses. GDM was not examined individually due to insufficient numbers. Log-Poisson models were used to estimate relative risks (RR) and 95% CIs for associations between preconception sleep characteristics, and pregnancy loss or adverse pregnancy outcomes with adjustment for age, BMI, lifestyle, and sociodemographic factors. Stabilized inverse probability weights were applied to address potential selection bias from loss to follow-up and from restricting to pregnancy. MAIN RESULTS AND THE ROLE OF CHANCE: Preconception sleep characteristics were not associated with risk of pregnancy loss. Preconception sleep duration and sleep latency were not associated with risk of the composite adverse pregnancy outcome. Early preconception sleep midpoints were associated with a lower risk of the composite adverse pregnancy outcome (first vs second tertile RR; 0.63, 95% CI: 0.40, 0.98) and preconception social jetlag was associated with a higher risk of the composite adverse pregnancy outcome (>1 vs ≤1 h RR; 1.65, 95% CI: 1.11, 2.44). LIMITATIONS, REASONS FOR CAUTION: Preconception sleep was restricted to baseline self-report, which may be non-differentially misclassified and may underestimate these associations. The EAGeR study did not measure sleep during pregnancy. There were few adverse pregnancy outcomes and thus limited power to evaluate individual outcomes; the findings could be due to chance. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that preconception sleep is not associated with pregnancy loss, but preconception sleep timing may be relevant for risk of adverse pregnancy outcomes. Additional studies on preconception sleep and adverse pregnancy outcomes are needed given the potential impact of poor sleep on pregnancy outcomes. STUDY FUNDING/COMPETING INTEREST(S): Joshua R. Freeman and this work were supported by the Intramural Research Program Cancer Research Training Award, National Cancer Institute, National Institutes of Health (ZIA CP010197), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (Contract numbers: HHSN267200603423, HHSN267200603424, HHSN267200603426, HHSN275201300023I). Dr Silver received NIH funding through the listed contracts as site-PI for the original EAGeR trial at the University of Utah. Dr O’Brien reports receiving funding from the Star Legacy Foundation (paid to institution); an advisory board role at the Star Legacy Foundation; and receiving travel support from the Star Legacy Foundation. Dr Dunietz reports a role as Associate Editor at Human Reproduction and a role on the Journal Editorial Board of SLEEP. Dr Purdue-Smithe is an employee of Merck & Co. and has received stock compensation as an employee of Merck & Co. in the past 36 months. The work in this manuscript was completed before Dr Purdue-Smithe’s employment at Merck & Co. and is unrelated to Dr Purdue-Smithe’s work at the company. Dr Silver reports royalties or licenses from BJOG and UpToDate, Inc. in the past 36 months, receiving payment or honoraria for Grand Rounds in the past 36 months, and participating on a Data Safety Monitoring Board or Advisory Board for a National Institutes of Health-funded Apple Trial in the past 36 months. The other authors report there are no competing interests to declare. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT00467363


  • Open Access

    Supplementary Table S1 from Sleep and Risk of Pancreatic Cancer in the UK Biobank

    by Joshua R. Freeman, Pedro F. Saint-Maurice, Ting Zhang, Charles E. Matthews, Rachael Z. Stolzenberg-Solomon

    Supplementary Table S1. P-values for interactions between smoking status, sex, and age, and the sleep characteristic and PDAC associations.

  • Open Access

    Supplementary Table S1 from Sleep and Risk of Pancreatic Cancer in the UK Biobank

    by Joshua R. Freeman, Pedro F. Saint-Maurice, Ting Zhang, Charles E. Matthews, Rachael Z. Stolzenberg-Solomon

    Supplementary Table S1. P-values for interactions between smoking status, sex, and age, and the sleep characteristic and PDAC associations.

  • Open Access

    Data from Sleep and Risk of Pancreatic Cancer in the UK Biobank

    by Joshua R. Freeman, Pedro F. Saint-Maurice, Ting Zhang, Charles E. Matthews, Rachael Z. Stolzenberg-Solomon

    Background:Light at night, which may cause circadian disruption, is a potential pancreatic cancer risk factor. However, evidence from related exposures such as poor sleep health and shift work remains inconclusive and sparsely investigated.Methods:We evaluated associations between self-reported typical sleep duration, chronotype, shift work, insomnia symptoms, snoring, and daytime sleeping and pancreatic ductal adenocarcinomas (PDAC) incidence among 475,286 UK Biobank participants. We used Cox proportional hazards models to estimate HRs and 95% confidence intervals (CI) adjusting for age, sex, body mass index, smoking status, duration, and frequency, alcohol intake, diabetes status, race, and employment/shift work.Results:Over 14 years of follow-up, 1,079 adults were diagnosed with PDAC. There were no associations observed between sleep characteristics, including sleep duration [<7 vs. 7–<9 hours; HR, 1.03; 95% CI, 0.90–1.19; ≥9 hours; HR, 1.00 (0.81–1.24), evening chronotype (“definitely” an evening person vs. “definitely” a morning person; HR, 0.99 (0.77–1.29)], shift work, insomnia symptoms, snoring, or daytime sleep and PDAC risk.Conclusions:Self-reported typical sleep characteristics and shift work were not associated with PDAC risk.Impact:Considering the role of light at night and shift work in circadian disruption and cancer risk, it is plausible that poor sleep health among a general population may be related to cancer risk through similar sleep and circadian disrupting processes. This work may suggest that typical sleep characteristics and shift work are not associated with PDAC, although additional work is needed to confirm these findings.

  • Open Access

    Data from Sleep and Risk of Pancreatic Cancer in the UK Biobank

    by Joshua R. Freeman, Pedro F. Saint-Maurice, Ting Zhang, Charles E. Matthews, Rachael Z. Stolzenberg-Solomon

    Background:Light at night, which may cause circadian disruption, is a potential pancreatic cancer risk factor. However, evidence from related exposures such as poor sleep health and shift work remains inconclusive and sparsely investigated.Methods:We evaluated associations between self-reported typical sleep duration, chronotype, shift work, insomnia symptoms, snoring, and daytime sleeping and pancreatic ductal adenocarcinomas (PDAC) incidence among 475,286 UK Biobank participants. We used Cox proportional hazards models to estimate HRs and 95% confidence intervals (CI) adjusting for age, sex, body mass index, smoking status, duration, and frequency, alcohol intake, diabetes status, race, and employment/shift work.Results:Over 14 years of follow-up, 1,079 adults were diagnosed with PDAC. There were no associations observed between sleep characteristics, including sleep duration [<7 vs. 7–<9 hours; HR, 1.03; 95% CI, 0.90–1.19; ≥9 hours; HR, 1.00 (0.81–1.24), evening chronotype (“definitely” an evening person vs. “definitely” a morning person; HR, 0.99 (0.77–1.29)], shift work, insomnia symptoms, snoring, or daytime sleep and PDAC risk.Conclusions:Self-reported typical sleep characteristics and shift work were not associated with PDAC risk.Impact:Considering the role of light at night and shift work in circadian disruption and cancer risk, it is plausible that poor sleep health among a general population may be related to cancer risk through similar sleep and circadian disrupting processes. This work may suggest that typical sleep characteristics and shift work are not associated with PDAC, although additional work is needed to confirm these findings.

  • Sleep and Risk of Pancreatic Cancer in the UK Biobank

    by Joshua R. Freeman, Pedro F. Saint-Maurice, Ting Zhang, Charles E. Matthews, Rachael Z. Stolzenberg-Solomon

    Background: Light at night, which may cause circadian disruption, is a potential pancreatic cancer risk factor. However, evidence from related exposures such as poor sleep health and shift work remains inconclusive and sparsely investigated. Methods: We evaluated associations between self-reported typical sleep duration, chronotype, shift work, insomnia symptoms, snoring, and daytime sleeping and pancreatic ductal adenocarcinomas (PDAC) incidence among 475,286 UK Biobank participants. We used Cox proportional hazards models to estimate HRs and 95% confidence intervals (CI) adjusting for age, sex, body mass index, smoking status, duration, and frequency, alcohol intake, diabetes status, race, and employment/shift work. Results: Over 14 years of follow-up, 1,079 adults were diagnosed with PDAC. There were no associations observed between sleep characteristics, including sleep duration [<7 vs. 7–<9 hours; HR, 1.03; 95% CI, 0.90–1.19; ≥9 hours; HR, 1.00 (0.81–1.24), evening chronotype (“definitely” an evening person vs. “definitely” a morning person; HR, 0.99 (0.77–1.29)], shift work, insomnia symptoms, snoring, or daytime sleep and PDAC risk. Conclusions: Self-reported typical sleep characteristics and shift work were not associated with PDAC risk. Impact: Considering the role of light at night and shift work in circadian disruption and cancer risk, it is plausible that poor sleep health among a general population may be related to cancer risk through similar sleep and circadian disrupting processes. This work may suggest that typical sleep characteristics and shift work are not associated with PDAC, although additional work is needed to confirm these findings.


  • Characterizing ActiGraph’s Idle Sleep Mode in Free-Living Assessments of Physical Behavior

    by Samuel R. LaMunion, Robert J. Brychta, Joshua R. Freeman, Pedro F. Saint-Maurice, Charles E. Matthews, Asuka Ishihara, Kong Y. Chen

    ActiGraph’s idle sleep mode (ISM) is an optional battery- and memory-conserving feature believed to engage during periods of nonwear, inactivity, and sleep, but it has not been well studied in free-living environments. Thus, we investigated ISM during a 7-day assessment in a nationally representative sample of 13,649 participants (6–80 years) in the United States and found it engaged 43.6% ± 0.2% (mean ± SE) of the 24 hr per day. ISM engagement was highest (78.4% ± 0.2%) during early morning (00:00–05:59) and lowest (20.4% ± 0.3%) during afternoon (12:00–17:59), corresponding to quadrants of lowest and highest of movement, respectively. ISM engagement was also inversely correlated with daily activity across all participants (R = −.72, p < .001). When restricted to participants averaging ≥21 hr per day of wear (N = 10,482), ISM still engaged 39.5% ± 0.2% of the day and inversely correlated to daily activity (R = −.58, p < .001). These results suggest ISM engages in activity level-dependent temporal patterns. Additional research is needed to better inform analyses and interpretation of ISM-enabled data including whether it is appropriate to process them with existing methods that were developed and validated using data without ISM enabled. This issue may be particularly relevant for methods used to detect and score sleep, as ISM engaged during a substantial portion of the typical overnight sleep period in the 8-hr window between ≥22:00 and SD).


  • Open Access

    Associations between actigraphy-measured sleep duration, continuity, and timing with mortality in the UK Biobank

    by Pedro F Saint-Maurice, Joshua R Freeman, Daniel Russ, Jonas S Almeida, Marissa M Shams-White, Shreya Patel, Dana L Wolff-Hughes, Eleanor L Watts, Erikka Loftfield, Hyokyoung G Hong, et al.

    To examine the associations between sleep duration, continuity, timing, and mortality using actigraphy among adults. Data were from a cohort of 88,282 adults (40-69yrs) in UK Biobank that wore a wrist-worn triaxial accelerometer for 7-days. Actigraphy data were processed to generate estimates of sleep duration and other sleep characteristics including wake after sleep onset (WASO), number of 5-min awakenings, and midpoint for sleep onset/wake-up and the least active 5 hours (L5). Data were linked to mortality outcomes with follow-up to 10/31/21. We implemented Cox models (Hazard ratio, confidence intervals [HR, 95% CI]) to quantify sleep associations with mortality. Models were adjusted for demographics, lifestyle factors, and medical conditions. Over an average of 6.8 years 2,973 deaths occurred (1,700 cancer, 586 CVD deaths). Overall sleep duration was significantly associated with risk for all-cause (p≥3:30: 1.19 [1.07, 1.32]). Shorter sleep duration and both early and late sleep timing were associated with a higher mortality risk. These findings reinforce the importance of public health efforts to promote healthy sleep patterns in adults.


  • Open Access

    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank

    by Joshua R Freeman, Pedro F Saint-Maurice, Eleanor L Watts, Steven C Moore, Marissa M Shams-White, Dana L Wolff-Hughes, Daniel E Russ, Jonas S Almeida, Neil E Caporaso, Hyokyoung G Hong, et al.

    Background: Studies of sleep and prostate cancer are almost entirely based on self-report, with limited research using actigraphy. Our goal was to evaluate actigraphy-measured sleep and prostate cancer and to expand on findings from prior studies of self-reported sleep. Methods: We prospectively examined 34 260 men without a history of prostate cancer in the UK Biobank. Sleep characteristics were measured over 7 days using actigraphy. We calculated sleep duration, onset, midpoint, wake-up time, social jetlag (difference in weekend-weekday sleep midpoints), sleep efficiency (percentage of time spent asleep between onset and wake-up time), and wakefulness after sleep onset. Cox proportional hazards models were used to estimate covariate-adjusted hazards ratios (HRs) and 95% confidence intervals (CIs). Results: Over 7.6 years, 1152 men were diagnosed with prostate cancer. Sleep duration was not associated with prostate cancer risk. Sleep midpoint earlier than 4:00 am was not associated with prostate cancer risk, though sleep midpoint of 5:00 am or later was suggestively associated with lower prostate cancer risk but had limited precision (earlier than 4:00 am vs 4:00-4:59 am HR = 1.00, 95% CI = 0.87 to 1.16; 5:00 am or later vs 4:00-4:59 am HR = 0.79, 95% CI = 0.57 to 1.10). Social jetlag was not associated with greater prostate cancer risk (1 to <2 hours vs <1 hour HR = 1.06, 95% CI = 0.89 to 1.25; ≥2 hours vs <1 hour HR = 0.90, 95% CI = 0.65 to 1.26). Compared with men who averaged less than 30 minutes of wakefulness after sleep onset per day, men with 60 minutes or more had a higher risk of prostate cancer (HR = 1.20, 95% CI = 1.00 to 1.43). Conclusions: Of the sleep characteristics studied, higher wakefulness after sleep onset—a measure of poor sleep quality—was associated with greater prostate cancer risk. Replication of our findings between wakefulness after sleep onset and prostate cancer are warranted.


  • Preconception sleep duration, sleep timing, and shift work in association with fecundability and live birth among women with a history of pregnancy loss

    by Joshua R. Freeman, Brian W. Whitcomb, Elizabeth R. Bertone-Johnson, Laura B. Balzer, Louise M. O’BRien, Galit L. Dunietz, Alexandra C. Purdue-Smithe, Keewan Kim, Robert M. Silver, Enrique F. Schisterman, et al.